Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans
Its topical supplementation offers multiple structural benefits: Repair and regeneration: promotes natural epidermal repair processes
As succinate accumulates via the inhibition of the 2-OGDD enzyme, epigenetic modification acts in the process of cell transformation into a hypermethylated phenotype 100
Delivery times for international orders are estimates only and may vary due to customs processing and local postal services
Its a convenient way and designed to help you shed those extra pounds, with them stating that thanks to their new program (medication + coaching), people can lose up to 48% more weight
injuries received in combat, etc
